Article Figures & Data
Figures
- FIGURE 1.
Typical 131I-MIBG blood time–activity concentration curve. Data points represent measured values and curve best-fit function, with initial component having zero-time intercept of 891.7 kBq (24.1 μCi)/mL (94% of activity in blood) and biologic half-life of 1.88 h and second component having zero-time intercept of 55.5 kBq (1.5 μCi)/mL (6% of activity in blood) and biologic half-life of 23.9 h. ID = injected dose.
Tables
Dose administered Response Survival Patient no. Age at treatment (y) MYCN status No. of prior relapses Prestudy status Prestudy 123I-MIBG score Actual 131I-MIBG (MBq/kg) Arsenic trioxide (mg/kg/d) INRC Relative 131I-MIBG score Progression-free survival (mo) Overall survival (mo) MP 1 9.8 N/A 1 SD 7 656.6 0.15 N/A 1.00 63.1* 63.1* 2 13.3 N/A 1 SD 9 668.4 0.15 N/A 1.00 100.2* 100.2* NB 3 9.2 NA 1 SD 13 444 0.15 NR 0.85 100.6* 100.6* 4 7.7 NA 0 SD 11 462.5 0.15 NR 1.00 79.2 99.0* 5 9.9 NA 1 SD 8 673.2 0.15 NR 0.88 94.1* 94.1* 6 6.0 NA 2 PD 6 669.7 0† NR 1.00 6.5 15.5 7 2.0 Ampl 0 SD 2‡ 647.5 0.25 NR 1.00 91.8* 91.8* 8 2.8 NA 1 SD 20 677.1 0.25 NR 1.00 83.3* 83.3* 9 3.3 Ampl 2 PD 2‡ 662.3 0.25 PD 1.00 0.9 3.7 10 4.7 NA 0 SD 14 632.7 0.25 NR 1.00 71.8* 71.8* 11 5.8 NA 5 PD 2‡ 662.3 0.25 PD 1.00 0.7 4.8 12 6.1 Ampl 2 PD 21 691.9 0.25 PD 0.90 2.8 4.0 13 6.1 NA 4 PD 2‡ 677.1 0.25 PD 1.00 1.4 8.7 14 6.2 Ampl 3 SD 5 662.3 0.25 PD 1.00 6.5 14.4 15 7.8 NA 4 SD 13 636.4 0.25 NR 1.00 3.7 14.7 16 8.3 NA 3 SD 21 658.6 0.25 NR 0.95 3.6 8.8 17 8.4 NA 0 SD 9 684.5 0.25 NR 0.88 83.3* 83.3* 18 8.4 NA 1 PD 10 654.9 0.25 PD 1.30 1.2 27.2 19 8.7 NA 3 PD 6 688.2 0.25 PD 1.50 1.2 9.8 20 15.2 NA 1 SD 9 647.5 0.25 NR 1.00 6.2 23.7 21 30.4 NA 2 PD 8 658.6 0.25§ NR 0.63 11.5 61.6 ↵* Continue to be progression-free.
↵† Arsenic trioxide not administered because of central-line–induced arrhythmia.
↵‡ MIBG–avid soft-tissue disease only.
↵§ Only 6 of 10 planned arsenic trioxide doses were administered because of diarrhea and electrolyte imbalance.
INRC = International Neuroblastoma Response Criteria; NB = neuroblastoma; N/A = not applicable; NA = not amplified; Ampl = amplified; SD = stable disease; PD = progressive disease; NR = no response.
Grade Toxicity 1 2 3 4 Symptomatology Diarrhea 5 4 1 0 Vomiting 8 7 1 0 Dry skin 2 1 0 0 Headache 0 1 0 0 Anorexia 1 0 0 0 Pain (cheek) 2 0 0 0 Dry mouth 1 0 0 0 Fatigue 1 0 0 0 Laboratory values Anemia 0 7 12 0 Neutropenia 0 3 8 8 Thrombocytopenia 1 2 3 15 Lymphopenia 0 0 3 15 Hypokalemia 6 2 1 0 Hyponatremia 7 0 1 0 Hypermagnesemia 2 0 0 0 Elevated serum creatinine 1 0 0 0 Elevated serum AST 7 0 0 0 Elevated serum ALT 9 0 0 0 Hyperbilirubinemia 1 0 0 0 Hyperamylasemia* 0 0 12 0 ↵* Serum amylase levels were measured in 13 patients.
AST = aspartate transaminase; ALT = alanine transaminase.
Site of disease No. of patients Objective response Objective response rate Soft tissue 9 0 0% Bone marrow (by histology) 6 0 0% Skeleton (by 131I-MIBG scan) 15 6 40% There were no major responses as assessed by International Neuroblastoma Response Criteria.
